Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer

NCT02299141 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Non-Small Cell Lung Cancer
Nonsmall Cell Lung Cancer

Interventions

DRUG: Nintedanib

Sponsor

Washington University School of Medicine

Collaborators

[object Object]